Compare Suven Life Sciences with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES PIRAMAL ENTERPRISES SUVEN LIFE SCIENCES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -105.1 -40.7 - View Chart
P/BV x 1.6 1.4 120.2% View Chart
Dividend Yield % 1.4 1.7 82.5%  

Financials

 SUVEN LIFE SCIENCES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
PIRAMAL ENTERPRISES
Mar-19
SUVEN LIFE SCIENCES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3383,303 10.2%   
Low Rs1691,797 9.4%   
Sales per share (Unadj.) Rs52.1716.5 7.3%  
Earnings per share (Unadj.) Rs6.879.7 8.6%  
Cash flow per share (Unadj.) Rs8.6107.9 7.9%  
Dividends per share (Unadj.) Rs1.5028.00 5.4%  
Dividend yield (eoy) %0.61.1 53.9%  
Book value per share (Unadj.) Rs65.31,477.5 4.4%  
Shares outstanding (eoy) m127.28184.45 69.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.93.6 136.7%   
Avg P/E ratio x37.132.0 116.0%  
P/CF ratio (eoy) x29.623.6 125.2%  
Price / Book Value ratio x3.91.7 225.0%  
Dividend payout %22.035.1 62.5%   
Avg Mkt Cap Rs m32,272470,292 6.9%   
No. of employees `0001.17.8 13.8%   
Total wages/salary Rs m66122,504 2.9%   
Avg. sales/employee Rs Th6,132.216,899.4 36.3%   
Avg. wages/employee Rs Th611.12,877.7 21.2%   
Avg. net profit/employee Rs Th803.51,879.9 42.7%   
INCOME DATA
Net Sales Rs m6,635132,153 5.0%  
Other income Rs m2423,128 7.7%   
Total revenues Rs m6,877135,281 5.1%   
Gross profit Rs m1,60466,290 2.4%  
Depreciation Rs m2215,202 4.3%   
Interest Rs m3844,097 0.1%   
Profit before tax Rs m1,58720,119 7.9%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7188,611 8.3%   
Profit after tax Rs m86914,701 5.9%  
Gross profit margin %24.250.2 48.2%  
Effective tax rate %45.242.8 105.7%   
Net profit margin %13.111.1 117.8%  
BALANCE SHEET DATA
Current assets Rs m6,232122,742 5.1%   
Current liabilities Rs m1,490310,810 0.5%   
Net working cap to sales %71.5-142.3 -50.2%  
Current ratio x4.20.4 1,059.1%  
Inventory Days Days8623 374.7%  
Debtors Days Days8339 212.7%  
Net fixed assets Rs m4,043116,904 3.5%   
Share capital Rs m127369 34.5%   
"Free" reserves Rs m8,183272,161 3.0%   
Net worth Rs m8,310272,530 3.0%   
Long term debt Rs m18270,196 0.0%   
Total assets Rs m10,389856,261 1.2%  
Interest coverage x43.11.5 2,960.1%   
Debt to equity ratio x01.0 0.2%  
Sales to assets ratio x0.60.2 413.8%   
Return on assets %8.76.9 127.2%  
Return on equity %10.55.4 194.0%  
Return on capital %19.512.4 157.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62215,200 37.0%   
Fx outflow Rs m1,7994,889 36.8%   
Net fx Rs m3,82210,312 37.1%   
CASH FLOW
From Operations Rs m356-115,975 -0.3%  
From Investments Rs m-279-8,265 3.4%  
From Financial Activity Rs m-225107,525 -0.2%  
Net Cashflow Rs m-148-16,650 0.9%  

Share Holding

Indian Promoters % 63.4 52.9 119.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.0 -  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 16.5 221.2%  
Shareholders   37,287 93,274 40.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  JUBILANT PHARMOVA   SUN PHARMA  IPCA LABS  

Compare SUVEN LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Lower Oxygen Supplies to Affect 5 Sectors, Tata Steel's Blockchain Transaction, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a positive note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 375 points (up 0.8%).

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Apr 22, 2021 (Close)

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS